Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Epizyme got the green light to resume enrollment in trials of the EZH2 inhibitor after showing the FDA data on the risk of secondary malignancies.
Around half the patients in the higher-doses cohorts experienced vision improvements, encouraging Nightstar to move NSR-RPGR into phase 2.
Two months after Sarepta was hit with a clinical hold by the FDA, the rare disease biotech has seen this lifted after sorting out a quality blip.
Using CRISPR screening, a UT Southwestern team found an interferon-stimulated gene that's key to resisting Zika.
Researchers from Cincinnati Children’s have grown esophageal organoids entirely from stem cells. Their work could yield treatments for GI diseases.
Luciole Medical raised about $5.5 million to commercialize its minimally invasive probe for measuring blood oxygen levels in the brain.
Roche and Foundation Medicine launched a blood test, analyzing 70 genes known to drive solid tumor growth, to guide precision cancer treatments.
Former Merck clinical research leader Arthur Santora is coming out of retirement to serve as chief medical officer of Entera Bio.
MeMed raised $70 million for its immune system diagnostic for distinguishing between bacterial and viral infections, to reduce antibiotic misuse.
uBiome, which sells sequencing-based microbiome tests, is moving into therapeutics with $83 million in new funding, a new site and a new board member.